
|Articles|December 10, 2013
New Therapies in Development for Multiple Myeloma
Author(s)Joseph R. Mikhael, MD
In this video, Dr. Mikhael discusses the current treatment paradigm for multiple myeloma and highlights some of the new agents in development.
Advertisement
Joseph R. Mikhael, MD, of the Mayo Clinic in Arizona, discusses the current treatment paradigm for multiple myeloma and highlights some of the new agents in development for multiple myeloma, both for treatment-naive and relapsed refractory patients, including the next-generation novel proteasome inhibitors, ixazomib (MLN9708) and oprozomib. Dr. Mikhael also highlights several monoclonal antibodies.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
Unmet Needs, Combination Therapies, and the Future of CAR T Consolidation in MCL
2
FDA Accepts Topical Gel sNDA for Superficial Basal Cell Carcinoma
3
FDA Removes Black Box Warning for Breast Cancer and Other Indications on HRT Products
4
Advances in Immunotherapy for Breast Cancer
5










































